MetaCap

Cue Biopharma Inc. (CUE)

NASDAQ: CUEHealth CareBiotechnology: Pharmaceutical PreparationsUSD

4.15-0.35 (-7.78%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CUE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$34.69M
EPS (TTM)
-$27.80
52-week range
2.83 – 45.50
Day range
4.05 – 4.90
Volume / Avg
1.26M / 567.02K
Beta
—

52-week range

$2.83$45.50

CUE stock today

Cue Biopharma (CUE) closed at $4.15 on Nov 20, down 7.78% (-$0.35), versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 1.26M shares, a sign of unusually heavy trading. Shares are 90.9% below their 52-week high of $45.50, set on Jul 10, 2026 and 46.6% above the 52-week low of $2.83, near the bottom of the past year's range.

CUE is down 54.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 76.8%. Cue Biopharma has posted a net loss over the last twelve months (EPS of -$27.80), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cue Biopharma

Company profile

Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Shao-Lee Lin M.D., Ph.D.
Headquarters
Boston, MA
Employees
29
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Cue Biopharma generated $27.5 million in revenue, up 195.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Cue Biopharma reported a net loss of $26.6 million, compared with a loss of $40.7 million a year earlier. Operating margin was -96.7%.

Cue Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$27.47M$9.29M$5.49M$1.25M$14.94M
Growth+195.75%+69.16%+340.96%-91.67%+373.68%
Net income$-26.60M$-40.67M$-50.73M$-53.01M$-44.16M
EPS (diluted)$-0.28$-0.72$-1.11$-1.49$-1.41

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$88.00+2020.48%

  • Strong buy 0
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $66.00High $115.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-4.42 vs $-4.04
Surprise
-9.41%

CUE news

All CUE news

Cue Biopharma peers

Health Care sector
CUE peer companies
CompanyPrice% ChgMarket capCompare
GRCEGrace Therapeutics Inc.1.71-0.58%$35.97Mvs CUE
VERUVeru Inc.1.94-8.06%$33.08Mvs CUE
ATNMActinium Pharmaceuticals Inc. (Delaware)1.05-1.87%$33.01Mvs CUE
HYFTMindWalk Holdings Corp.0.6844-14.27%$32.56Mvs CUE
PLRXPliant Therapeutics Inc.0.5951-4.02%$36.89Mvs CUE
SDEVStablecoin Development Corporation0.50-10.30%$36.90Mvs CUE
GRDXGridAI Technologies Corp.3.16-8.41%$32.44Mvs CUE
FLNAFilana Therapeutics Inc.0.6413+14.52%$32.26Mvs CUE

Indexes, lists and sector

Cue Biopharma stock FAQ

What is Cue Biopharma's stock price today?

CUE last traded at $4.15 as of Nov 20, 4:00 PM EST, down 7.78% on the day. Prices are delayed at least 15 minutes.

Does Cue Biopharma pay a dividend?

No. Cue Biopharma does not currently pay a regular cash dividend.

Who is Cue Biopharma's CEO?

Dr. Shao-Lee Lin M.D., Ph.D. is the chief executive officer of Cue Biopharma Inc., which has about 29 employees.

Has CUE ever split its stock?

Yes. The most recent CUE stock split was a 1-for-30 split on Apr 24, 2026.

What is the CUE 52-week high?

The 52-week high for CUE is $45.50 and the 52-week low is $2.83. The stock is currently 90.9% below its high.

Compare CUE